Clinical use of [TIMP-2] •[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel

The first FDA-approved test to assess risk for acute kidney injury (AKI), [TIMP-2] •[IGFBP7], is clinically available in many parts of the world, including the USA and Europe. We sought to understand how the te...

Source: Critical Care - June 20, 2019 Category: Intensive Care Authors: Louis M. Guzzi, Tobias Bergler, Brian Binnall, Daniel T. Engelman, Lui Forni, Michael J. Germain, Eric Gluck, Ivan G öcze, Michael Joannidis, Jay L. Koyner, V. Seenu Reddy, Thomas Rimmelé, Claudio Ronco, Julien Textoris, Alexander Zarbock and John A. Ke Tags: Research Source Type: research